Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amakem NV

This article was originally published in Start Up

Executive Summary

Launched in early 2010 by former Devgen executives, Amakem NV joins the ranks of companies developing rho-kinase inhibitors for glaucoma. It is using its "Localized Drug Action" platform to limit the side effects common to most kinase inhibitors, a strategy it believes will provide an edge over competitors whose ROCK inhibitors are far more advanced.

You may also be interested in...



Altheos Inc.

At its inception, Altheos licensed a series of selective Rho-kinase inhibitors for glaucoma from Asahi Kasei Pharma, and it plans to move the lead candidate into clinical trials in the coming year. Although the start-up is behind several companies that already have ongoing ROCK inhibitor trials, Altheos believes its approach to drug discovery and medicinal chemistry make its therapeutic likely to prove itself the best among the new class of medicines for staving off vision loss from glaucoma.

Eyeing New Drugs For Glaucoma

Demographic shifts leading to an increasing market, unmet medical need and potential interest from Big Pharma buyers are all compelling reasons for VCs to examine closely the opportunity in glaucoma. Add in the fact that because clinical trials are relatively straightforward and quick, it's possible to keep costs manageable, and one might expect venture capitalists to be rushing to form biotech start-ups in the glaucoma arena, especially since there's been no new mechanism of action in glaucoma in a long time. But the hurdle giving venture investors pause is the wholesale restructuring that will come to the glaucoma market next March, when a key patent for Xalatan expires.

Start-Up Previews (10/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel